Bone metastases in gastrointestinal cancer

Clinical and Experimental Metastasis

Volumn 32, Issue 1, 2015, Pages 7-14

  Portales, Fabienne ^a   Thézenas, Simon ^a   Samalin, Emmanuelle ^a   Assenat, Eric ^a,b   Mazard, Thibault ^a,b   Ychou, Marc ^a  

^a CENTRE VAL D AURELLE   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Bone metastasis; Colorectal cancer; Esophageal cancer; Gastric cancer; Metastasis; Skeletal related event

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GASTROESOPHAGEAL CANCER; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PATHOLOGIC FRACTURE; PRIMARY TUMOR; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; VISCERAL METASTASIS; BONE NEOPLASMS; GASTROINTESTINAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84928300267     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9686-x     Document Type: Article

References (36)

1. Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M (2010) Gastrointestinal and liver tumours and public health in Europe. Eur Rev Med Pharmacol Sci 14:259–262
2. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9:14–27. doi:10.1634/theoncologist.9-90004-14
3. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593. doi:10.1038/nrc867
4. Clamp A, Danson S, Nguyen H et al (2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5:607–616. doi:10.1016/S1470-2045(04)01596-7
5. Sundermeyer ML, Meropol NJ, Rogatko A et al (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113
6. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016. doi:10.1016/S0140-6736(08)60455-9
7. Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835. doi:10.1200/JCO.2008.19.9273
8. Olivier T, Gastaud L, Maschi C et al (2014) Metastasis to unusual sites. Bull Cancer (Paris). doi:10.1684/bdc.2014.1889
9. Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867. doi:10.1002/cncr.22991
10. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468. doi:10.1093/jnci/94.19.1458
11. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1792. doi:10.1056/NEJM199612123352401
12. Silvestris N, Pantano F, Ibrahim T et al (2013) Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS ONE 8:e74402. doi:10.1371/journal.pone.0074402
13. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
14. Roth ES, Fetzer DT, Barron BJ et al (2009) Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 9:274. doi:10.1186/1471-2407-9-274
15. Santini D, Tampellini M, Vincenzi B et al (2012) Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:2072–2077. doi:10.1093/annonc/mdr572
16. Besbeas S, Stearns MW Jr (1978) Osseous metastases from carcinomas of the colon and rectum. Dis Colon Rectum 21:266–268
17. Kanthan DR, Loewy J, Kanthan SC (1999) Skeletal metastases in colorectal carcinomas. Dis Colon Rectum 42:1592–1597. doi:10.1007/BF02236213
18. Katoh M, Unakami M, Hara M, Fukuchi S (1995) Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol 30:615–618
19. Welch JP, Donaldson GA (1979) The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 189:496–502
20. Park JM, Song KY, O JH et al (2013) Bone recurrence after curative resection of gastric cancer. Gastric Cancer 16:362–369. doi:10.1007/s10120-012-0193-y
21. Park HS, Rha SY, Kim HS et al (2011) A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology 80:142–150. doi:10.1159/000328507
22. Dennis K, Wong K, Zhang L et al (2011) Palliative radiotherapy for bone metastases in the last 3 months of life: worthwhile or futile? Clin Oncol 23:709–715. doi:10.1016/j.clon.2011.05.004
23. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev Online CD003474. doi:10.1002/14651858.CD003474.pub2
24. Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi:10.1200/JCO.2010.29.7101
25. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882
26. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621. doi:10.1002/cncr.20308
27. Patel LR, Camacho DF, Shiozawa Y et al (2011) Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol Lond Engl 7:1285–1297. doi:10.2217/fon.11.112
28. Janni W, Vogl FD, Wiedswang G et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 17:2967–2976. doi:10.1158/1078-0432.CCR-10-2515
29. Morgan TM, Lange PH, Porter MP et al (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15:677–683. doi:10.1158/1078-0432.CCR-08-1754
30. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46. doi:10.1056/NEJMoa073149
31. Lee J, Lim T, Uhm JE et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891. doi:10.1093/annonc/mdl501
32. Hernandez RK, Maegbaek ML, Liede A et al (2014) Bone metastases, skeletal-related events, and survival among children with cancer in Denmark. J Pediatr Hematol Oncol. doi:10.1097/MPH.0000000000000106
33. Peugniez C, Hiret S, Galais M-P et al (2014) Les facteurs prédictifs de contrôle tumoral des carcinomes épidermoïdes métastatiques de l’oesophage traités par chimiothérapie à base de sels de platine: premiers résultats de l’étude E-DIS. In: JFHOD congress, Paris, France, p 108, #CO.87. http://www.snfge.org/sites/default/files/SNFGE/JFHOD/livre-resumes-jfhod-2014-vfinale.pdf
34. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30. doi:10.1200/JCO.2004.09.046
35. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132. doi:10.1200/JCO.2010.31.3304
36. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432. doi:10.1093/annonc/mdm442